Articles By Nelly Ziade
Biologic Class Determines PsA Risk in Psoriasis
By Nelly Ziade
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
Read Article
La clase de fármaco biológico determina el riesgo de artritis psoriásica en la psoriasis
By Nelly Ziade
En EULAR 2026, el Dr. Nikolaos Kougkas presentó datos de una cohorte única del mundo real creada en centros universitarios conjuntos de dermatología y reumatología, que siguió a 394 pacientes con psoriasis en tratamiento con FAMEb durante un máximo de 17 años. Nos sentamos con el Dr. Kougkas para analizar la metodología, cuestionar los resultados y extraer las implicaciones clínicas para la práctica diaria.
Read Article
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
By Nelly Ziade
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.
Read Article
Más allá de la báscula: ¿Ofrecen los AR-GLP-1 más que la pérdida de peso en la APs?
By Nelly Ziade
Más del 70 % de los pacientes con APs tienen problemas de sobrepeso, lo que amplifica la inflamación sinovio-entesial y reduce la respuesta biológica. La rápida adopción de los AR GLP-1 en reumatología ha planteado una pregunta mecanística urgente: ¿las mejoras clínicas en la APs se deben únicamente a la reducción de peso, o estos agentes poseen propiedades antiinflamatorias intrínsecas? EULAR 2026 presentó seis resúmenes que en conjunto arrojan luz, sin resolverla del todo, sobre esta cuestión.
Read Article
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
By Nelly Ziade
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.
Read Article
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
By Nelly Ziade
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.
Read Article
Predicting Psoriatic Arthritis in Psoriasis: How Close Are We?
By Nelly Ziade
Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies highlighted progress in prediction strategies. Here's my review of three of them.
Read Article
Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors
By Nelly Ziade
The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.
Read Article
